Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators

[1]  A. Hamsten,et al.  Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients , 1996, The Lancet.

[2]  J. Auwerx,et al.  Peroxisome proliferator-activated receptors, orphans with ligands and functions. , 1997, Current opinion in lipidology.

[3]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[4]  J. Auwerx,et al.  Tissue Distribution and Quantification of the Expression of mRNAs of Peroxisome Proliferator–Activated Receptors and Liver X Receptor-α in Humans: No Alteration in Adipose Tissue of Obese and NIDDM Patients , 1997, Diabetes.

[5]  D. McTavish,et al.  Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. , 1990, Drugs.

[6]  I. Adcock,et al.  Evidence for Involvement of NF-κB in the Transcriptional Control of COX-2 Gene Expression by IL-1β ☆ , 1997 .

[7]  A. Rebuzzi,et al.  The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.

[8]  P. A. Todd,et al.  Gemfibrozil , 2012, Drugs.

[9]  R. White,et al.  Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[10]  清 斉藤,et al.  抗高脂血症薬フェノフィブラートの抗動脈硬化作用(I)コレステロール負荷ウサギにおける血清脂質低下作用を介さない抗動脈硬化作用 , 1995 .

[11]  M. Iino.  Intracellular Ca2+ stores and vascular smooth muscle contraction , 1995 .

[12]  H. Herschman,et al.  Transcriptional Regulation of Prostaglandin Synthase 2 Gene Expression by Platelet-derived Growth Factor and Serum* , 1996, The Journal of Biological Chemistry.

[13]  J. Maclouf,et al.  Enzyme immunoassays of eicosanoids using acetylcholine esterase as label: an alternative to radioimmunoassay. , 1985, Analytical chemistry.

[14]  R. Ross.  The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[15]  A. Tedgui,et al.  Increased production of tumor necrosis factor and interleukin-6 by arterial wall of aged rats. , 1995, The American journal of physiology.

[16]  S. Thompson,et al.  Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. , 1995, The New England journal of medicine.

[17]  J. Maclouf,et al.  Demonstration of an inducible cyclooxygenase in human endothelial cells using antibodies raised against the carboxyl-terminal region of the cyclooxygenase-2. , 1993, The Journal of biological chemistry.

[18]  Allan Bradley,et al.  Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice , 1991, Cell.

[19]  A. Clauss,et al.  Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens , 1957 .

[20]  David A Jones,et al.  Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. , 1993, The Journal of biological chemistry.

[21]  P. Libby,et al.  The Nuclear Factor κ-B Signaling Pathway Participates in Dysregulation of Vascular Smooth Muscle Cells in Vitroand in Human Atherosclerosis* , 1997, The Journal of Biological Chemistry.

[22]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[23]  Kei Yamamoto,et al.  Transcriptional Roles of Nuclear Factor B and Nuclear Factor-Interleukin-6 in the Tumor Necrosis Factor -Dependent Induction of Cyclooxygenase-2 in MC3T3-E1 Cells (*) , 1995, The Journal of Biological Chemistry.

[24]  J. Auwerx,et al.  Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. , 1995, The Journal of clinical investigation.

[25]  P. Libby,et al.  Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.

[26]  P. Libby,et al.  Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. , 1990, The Journal of clinical investigation.

[27]  J. Steitz,et al.  Human acidic ribosomal phosphoproteins P0, P1, and P2: analysis of cDNA clones, in vitro synthesis, and assembly , 1987, Molecular and cellular biology.

[28]  R. Knuechel,et al.  Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. , 1996, The Journal of clinical investigation.

[29]  Barry M. Forman,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ , 1997 .

[30]  B. Seed,et al.  PPAR-γ agonists inhibit production of monocyte inflammatory cytokines , 1998, Nature.

[31]  W. Wahli,et al.  The PPARα–leukotriene B4 pathway to inflammation control , 1996, Nature.